

FINAL REPORT

| Bill No. | : | APHHC240001945 | | | Bill Date | | 09-11-2024 09:26 | | | |
|------------------|-----|-----------------------|------|-----|-----------------------|-----|------------------|------------------|-----------------|--------|
| Patient Name | : | MRS. SAUMYA | | | UHID | | APH0000 | 30871 | | |
| Age / Gender | : | 35 Yrs 2 Mth / FEMALE | | | Patient Type | | OPD | | If PHC | : |
| Ref. Consultant | : | MEDIWHEEL | | | Ward / Bed | | 1 | | | |
| Sample ID | : | APH24052491 | | | Current Ward / Bed | | 1 | / | | |
| | : | | | | Receiving Date & Time | Ð | 09-11-202 | 4 10:13 | | |
| | Τ | | | | Reporting Date & Time | e | 09-11-202 | 4 11:23 | | |
| L | _ | Bl | OCHE | MIS | STRY REPORTING | | | | | |
| Test (Methodolog | gy) | | Flag | Re | esult l | UOM | | Biolog Interv | gical Ref al | erence |

Sample Type: EDTA Whole Blood, Serum

MEDIWHEEL FULL BODY HEALTH CHECKUP_FEMALE BELOW40@2550

| BLOOD UREA Urease-GLDH, Kinetic | 19 | mg/dL | 15 - 45 |
|---|-----|-------|-----------|
| BUN (Calculated) | 8.9 | mg/dL | 7 - 21 |
| | | | |
| CREATININE-SERUM (Modified Jaffe s Kinetic) | 0.6 | mg/dL | 0.6 - 1.1 |
| | | | |
| х — Т | | | |

(As per American Diabetes Association recommendation)

LIPID PROFILE

| CHOLESTROL-TOTAL (CHO-POD) | Н | 194 | mg/dL | 0-160 |
|--|----|-------|-------|---|
| HDL CHOLESTROL Enzymatic Immunoinhibition | L | 41 | mg/dL | >45 |
| CHOLESTROL-LDL DIRECT Enzymatic Selective Protection | Н | 127 | mg/dL | 0-100 |
| S.TRIGLYCERIDES (GPO - POD) | | 90 | mg/dL | 0-160 |
| NON-HDL CHOLESTROL (Calculated) | Н | 153.0 | mg/dL | 0-125 |
| CHOLESTROL-VLDL (Calculated) | | 18 | mg/dL | 10-35 |
| TOTAL CHOLESTROL / HDL CHOLESTROL (Calculated) | | 4.7 | | 1/2 Average Risk <3.3,Average Risk 3.3-4.4 , 2 Times Average Risk 4.5-7.1,3 Times Average Risk 7.2-11.0 |
| LDL CHOLESTROL / HDL CHOLESTROL (Calculated) | СН | 3.1 | | 1/2 Average Risk <1.5 , Average Risk 1.5-3.2 , 2 Times Average Risk 3.3-5.0 , 3 Times Average Risk 5.1-6.1 |

INTERPRETATION:

A lipid profile test measures the different types of lipids in the blood. It measures the levels of four different types of cholesterol and triglycerides. •LDL (low-density lipoproteins): LDL is the cholesterol that is considered "bad cholesterol" because it forms plaques in the arteries and adversely affects heart health. Thus, LDL cholesterol should be maintained in the lower range.

•VLDL (very low-density lipoproteins): VLDL appears in the blood soon after we have consumed food. A lipid profile is done as a fasting test, and thus, if there is an increased level of VLDL in the blood sample, it can be suggestive of some metabolic disease.

•HDL (high-density lipoproteins): HDL cholesterol is also known as "good cholesterol" because it helps clear away the bad LDL cholesterol and prevents its build-up.

•Total cholesterol: It is the sum of all the different types of cholesterol in your body, i.e., LDL + VLDL + HDL.

•Triglycerides: Our body converts the excess calories into triglycerides and stores it as body fat. High levels of triglycerides are harmful to the heart, liver, and pancreas.

LIVER FUNCTION TESTS (LFT)

| BILIRUBIN-TOTAL (DPD) | 0.54 | mg/dL | 0.2 - 1.0 |
|---|------|-------|-----------|
| BILIRUBIN-DIRECT (DPD) | 0.10 | mg/dL | 0 - 0.2 |
| BILIRUBIN-INDIRECT (Calculated) | 0.44 | mg/dL | 0.2 - 0.8 |
| S.PROTEIN-TOTAL (Biuret) | 7.0 | g/dL | 6 - 8.1 |
| ALBUMIN-SERUM (Dye Binding-Bromocresol Green) | 4.3 | g/dL | 3.5 - 5.2 |



| Bill No. | : | APHHC240001945 | | | Bill Date | | : | 09-11-2024 09:26 | 24 09:26 | | |
|-----------------|------------------------|------------------------------|-----------------------|-----|----------------------|------|------------------|------------------|----------|---|--|
| Patient Name | : | MRS. SAUMYA | | | UHID | | : | APH000030871 | | | |
| Age / Gender | : | 35 Yrs 2 Mth / FEMALE | | | Patient Type | | : | OPD If PHC : | | : | |
| Ref. Consultant | : | MEDIWHEEL | | | Ward / Bed | | : | 1 | | | |
| Sample ID | ample ID : APH24052491 | | | | Current Ward / Bed | | | . / | | | |
| | 1: | | Receiving Date & Time | | ne | : | 09-11-2024 10:13 | 4 10:13 | | | |
| | \top | | | | Reporting Date & Tir | ne | : | 09-11-2024 11:23 | i | | |
| S.GLOBULIN (| Calcu | lated) | L | 2. | 7 | g/dL | _ | 2.8-3.8 | 3 | | |
| A/G RATIO (Cal | culat | ed) | | 1.5 | 59 | | | 1.5 - 2 | 2.5 | | |
| ALKALINE PHO | DSF | PHATASE IFCC AMP BUFFER | | 72 | .3 | IU/L | | 42 - 98 | 3 | | |
| ASPARTATE A | MI | NO TRANSFERASE (SGOT) (IFCC) | | 27 | .9 | IU/L | | 10 - 42 | 2 | | |
| ALANINE AMII | ١O | TRANSFERASE(SGPT) (IFCC) | | 35 | .6 | IU/L | | 10 - 40 |) | | |
| GAMMA-GLUT | AM | YLTRANSPEPTIDASE (IFCC) | | 11 | .6 | IU/L | | 7 - 35 | | | |
| LACTATE DEH | YD | ROGENASE (IFCC; L-P) | | 16 | 9.6 | IU/L | | 0 - 24 | 8 | | |

INTERPRETATION:

The LFT test is used to diagnose and monitor liver diseases. It can also provide the information about other health conditions that affect the liver, such as viral or alcoholic hepatitis. If a person is taking medications that can impact on the liver, the test results can indicating whether side effects are occurring.

| S.PROTEIN-TOTAL (Biuret) | 7.0 | g/dL | 6 - 8.1 |
|-------------------------------|-----|-------|-----------|
| URIC ACID (Uricase - Trinder) | 5.3 | mg/dL | 2.6 - 7.2 |

INTERPRETATION:

High levels of uric acid could be a sign of gout, a condition characterized by inflammation of the joints due to the formation of uric acid crystals. The uric acid level also monitors of a person undergoing the chemotherapy or radiation treatment for cancer.

IMPORTANT INSTRUCTIONS

** End of Report **

CL - Critical Low, CH - Critical High, H - High, L - Low

Laboratory test results are to be clinically correlated.

Storage and discard of Specimen shall be as per AIMS specimen retention policy.

Test results are not valid for Medico - Legal purposes.

DR. ASHISH RANJAN SINGH MBBS,MD CONSULTANT



FINAL REPORT

| Bill No. | : | APHHC240001945 | Bill Date | | : | 09-11-2024 09:26 | | |
|-----------------|---|-----------------------|-----------------------|---|---|------------------|--------|---|
| Patient Name | : | MRS. SAUMYA | UHID | | : | APH000030871 | | |
| Age / Gender | : | 35 Yrs 2 Mth / FEMALE | Patient Type | | : | OPD | If PHC | : |
| Ref. Consultant | : | MEDIWHEEL | Ward / Bed | | : | 1 | | |
| Sample ID | : | APH24052491 | Current Ward / Bed | | : | 1 | | |
| | : | | Receiving Date & Time | ; | : | 09-11-2024 10:13 | | |
| | | | Reporting Date & Time | • | : | 09-11-2024 11:23 | | |

Sample Type: EDTA Whole Blood, Serum

MEDIWHEEL FULL BODY HEALTH CHECKUP FEMALE BELOW40@2550

| | HBA1C (Turbidimetric Immuno-inhibition) | 5.7 | % | 4.0 - 6.2 |
|------|---|-----|---|-----------|
| INTE | RPRETATION: | | | |

| HbA1c % | Degree of Glucose Control |
|-----------|--|
| >8% | Action suggested due to high risk of developing long term complications like Retinopathy, Nephropathy, Cardiopathy and Neuropathy |
| 7.1 - 8.0 | Fair Control |
| <7.0 | Good Control |

Note:

1.A three monthly monitoring is recommended in diabetics.2. Since HbA1c concentration represents the integrated values for blood glucose over the preceding 6 - 10 weeks and is not affected by daily glucose fluctuation, exercise and recent food intake, it is a more useful tool for monitoring diabetics.

** End of Report **

IMPORTANT INSTRUCTIONS

CL - Critical Low, CH - Critical High, H - High, L - Low

Laboratory test results are to be clinically correlated.

Storage and discard of Specimen shall be as per AIMS specimen retention policy.

Test results are not valid for Medico - Legal purposes.

DR. ASHISH RANJAN SINGH MBBSMD CONSULTANT



FINAL REPORT

| Bill No. | : | APHHC240001945 | | | Bill Date | | : | 09-11-2024 | 09:26 | | |
|----------------------|----------|---------------------------------|--------|------------|----------------------|-----|----------------------|------------|-------------------|-----------------|--------|
| Patient Name | : | MRS. SAUMYA | | | UHID | | : | APH000030 | 0871 | | |
| Age / Gender | : | 35 Yrs 2 Mth / FEMALE | | | Patient Type | | : | OPD | | If PHC | : |
| Ref. Consultant | : | MEDIWHEEL | | | Ward / Bed | | : | 1 | | | |
| Sample ID | : | APH24052523 | | | Current Ward / Bed | | : | : / | | | |
| | : | | | | Receiving Date & Tir | me | : | 09-11-2024 | | | |
| | | | | | Reporting Date & Tir | me | e : 09-11-2024 13:16 | | | | |
| | | <u>C</u> | LINICA | L P | ATH REPORTING | | | : | | | |
| Test (Methodology) | | | Flag | Re | esult | UO | М | | Biolog Interva | jical Ref al | erence |
| Sample Type: Urine | | | • | | | | | · | | | |
| MEDIWHEEL FUI | LL | BODY HEALTH CHECKUP_F | EMALE | BEI | LOW40@2550 | | | | | | |
| URINE, ROUTINE | E | XAMINATION | | | | | | | | | |
| PHYSICAL EXAN | IIN | ATION | | | | | | | | | |
| QUANTITY | QUANTITY | | | 20 | | | | | | | |
| COLOUR | COLOUR | | | Pale straw | | | | | Pale Ye | ellow | |
| TURBIDITY | | | | Cle | ear | | | | | | |
| CHEMICAL EXAN | MIN | IATION | | | | | | | | | |
| PH (Double pH indica | itor n | ethod) | | 6.0 |) | | | | 5.0 - 8.5 | | |
| PROTEINS (Prof | tein-e | rror-of-indicators) | | Ne | gative | | | | Negative | | |
| SUGAR (GOD POD |) Met | nod) | | Ne | gative | | | | Negativ | /e | |
| SPECIFIC GRA | ١V | TY, URINE (Apparent pKa change) | | 1.0 |)15 | | | | 1.005 - | 1.030 | |
| MICROSCOPIC E | XA | | | | | | | | | | |
| LEUCOCYTES | | | | 1-2 | 2 | /HP | F | | 0 - 5 | | |
| RBC's | | | | Nil | | | | | | | |
| EPITHELIAL C | EL | S | | 1-2 | 2 | | | | | | |
| CASTS | | | | Nil | | | | | | | |
| CRYSTALS | | | | Nil | | | | | | | |
| URINE-SUGAF | 2 | | | NE | GATIVE | | | | | | |
| | | | | | | | | | | | |
| | | | ** | End | of Report ** | | | | | | |

IMPORTANT INSTRUCTIONS

CL - Critical Low, CH - Critical High, H - High, L - Low

Laboratory test results are to be clinically correlated.

Storage and discard of Specimen shall be as per AIMS specimen retention policy.

Test results are not valid for Medico - Legal purposes.

Ashish

DR. ASHISH RANJAN SINGH MBBS,MD CONSULTANT



FINAL REPORT

| Bill No. | : | APHHC240001945 | Bill Date | : | 09-11-2024 09:26 | | |
|-----------------|---|-----------------------|-----------------------|---|------------------|----------|--|
| Patient Name | : | MRS. SAUMYA | UHID | : | APH000030871 | | |
| Age / Gender | : | 35 Yrs 2 Mth / FEMALE | Patient Type | : | OPD | If PHC : | |
| Ref. Consultant | : | MEDIWHEEL | Ward / Bed | : | 1 | · · · | |
| Sample ID | : | APH24052488 | Current Ward / Bed | : | 1 | | |
| | : | | Receiving Date & Time | : | 09-11-2024 10:13 | | |
| | | | Reporting Date & Time | : | 09-11-2024 12:12 | | |

HAEMATOLOGY REPORTING

| Test (Methodology) | Flag | Result | UOM | Biological Reference |
|--------------------|------|--------|-----|----------------------|
| | _ | | | Interval |

Sample Type: EDTA Whole Blood

MEDIWHEEL FULL BODY HEALTH CHECKUP_FEMALE BELOW40@2550

CBC -1 (COMPLETE BLOOD COUNT)

| TOTAL LEUCOCYTE COUNT (Flow Cytometry) | | 6.5 | thousand/cumm | 4 - 11 |
|---|---|------|---------------|-------------|
| RED BLOOD CELL COUNT (Hydro Dynamic Focussing) | | 4.2 | million/cumm | 3.8 - 4.8 |
| HAEMOGLOBIN (SLS Hb Detection) | L | 11.1 | g/dL | 12 - 15 |
| PACK CELL VOLUME (Cumulative Pulse Height Detection) | | 36.2 | % | 36 - 46 |
| MEAN CORPUSCULAR VOLUME (Calculated) | | 85.3 | fL | 83 - 101 |
| MEAN CORPUSCULAR HAEMOGLOBIN (Calculated) | L | 26.1 | pg | 27 - 32 |
| MEAN CORPUSCULAR HAEMOGLOBIN CONCENTRATION (Calculated) | L | 30.6 | g/dL | 31.5 - 34.5 |
| PLATELET COUNT (Hydro Dynamic Focussing) | | 161 | thousand/cumm | 150 - 400 |
| RED CELL DISTRIBUTION WIDTH (S.D - RDW) (Particle Size Distribution) | Н | 47.4 | fL | 39 - 46 |
| RED CELL DISTRIBUTION WIDTH (C.V.) | Н | 15.5 | % | 11.6 - 14 |

DIFFERENTIAL LEUCOCYTE COUNT

| NEUTROPHILS (Flow-cytometry & Microscopy) | | 70 | % | 40 - 80 |
|---|--|----|---|---------|
| LYMPHOCYTES (Flow-cytometry & Microscopy) | | 23 | % | 20 - 40 |
| MONOCYTES (Flow-cytometry & Microscopy) | | 5 | % | 2 - 10 |
| EOSINOPHILS (Flow-cytometry & Microscopy) | | 2 | % | 1 - 5 |
| BASOPHILS (Flow-cytometry & Microscopy) | | 0 | % | 0 - 1 |

INTERPRETATION:

A complete blood count (CBC) provides information about the different types and numbers of cells in the blood, including red blood cells, white blood cells, and platelets. It's used to look at overall health and find a wide range of conditions, including anaemia, infection, thrombocytopenia and leukemia.

| SR (Westergren) | Н | 53 | mm/1st hr | 0 - 20 |
|-----------------|---|----|-----------|--------|
|-----------------|---|----|-----------|--------|

INTERPRETATION:

An erythrocyte sedimentation rate show if there is inflammation in body. High ESR levels are often associated with various inflammatory conditions, infections, autoimmune diseases, and certain cancers. It can also indicate tissue damage or necrosis, as well as chronic diseases like rheumatoid arthritis, lupus, or vasculitis.

| ** End of Report ** | | | | | | | |
|--|--|--|--|--|--|--|--|
| IMPORTANT INSTRUCTIONS | | | | | | | |
| CL - Critical Low, CH - Critical High, H - High, L - Low | | | | | | | |

LL - Critical Low, CH - Critical Hign, H - Hign, L -Laboratory test results are to be clinically correlated.

Storage and discard of Specimen shall be as per AIMS specimen retention policy. Test results are not valid for Medico - Legal purposes.



DEPARTMENT OF LABORATORY SERVICES FINAL REPORT

| Bill No. | : | APHHC240001945 | Bill Date | : | 09-11-2024 09:26 | | |
|-----------------|---|-----------------------|-----------------------|---|------------------|----------|--|
| Patient Name | : | MRS. SAUMYA | UHID | : | APH000030871 | | |
| Age / Gender | : | 35 Yrs 2 Mth / FEMALE | Patient Type | : | OPD | If PHC : | |
| Ref. Consultant | : | MEDIWHEEL | Ward / Bed | : | 1 | | |
| Sample ID | : | APH24052488 | Current Ward / Bed | : | 1 | | |
| | : | | Receiving Date & Time | : | 09-11-2024 10:13 | | |
| | | | Reporting Date & Time | : | 09-11-2024 12:12 | | |



DR. ASHISH RANJAN SINGH MBBS,MD CONSULTANT

DEPARTMENT OF RADIO-DIAGNOSIS & IMAGING

Report : ULTRASOUND

| Patient Name | : | MRS. SAUMYA | IPD No. | : | |
|--------------|---|--------------|------------|---|---------------------|
| Age | : | 35 Yrs 2 Mth | UHID | : | APH000030871 |
| Gender | : | FEMALE | Bill No. | : | APHHC240001945 |
| Ref. Doctor | : | MEDIWHEEL | Bill Date | : | 09-11-2024 09:26:11 |
| Ward | : | | Room No. | : | |
| | | | Print Date | : | 09-11-2024 12:12:16 |

WHOLE ABDOMEN:

Both the hepatic lobes are normal in size and show grade I fatty infiltration (Liver measures 14.7 cm)

No focal lesion seen. Intrahepatic biliary radicals are not dilated.

Portal vein is normal in calibre.

Gall bladder is well distended. Wall thickness is normal. No calculus seen.

CBD is normal in calibre.

Pancreas is normal in size and echotexture.

Spleen is normal in size (10.89 cm) and echotexture.

Both kidneys are normal in size and echotexture (Right kidney (8.6 cm), Left kidney (10 cm). Cortico-

medullary distinction is maintained. No calculus or hydronephrosis seen.

Urinary bladder is distended and appears normal. Wall thickness is normal.

Uterus is retroverted (measures 7.6 x 3.8 cm) and appears normal in size and echotexture. No focal

lesion seen. Cervix and vagina are unremarkable.

Endometrial echo is central and normal in thickness (7.3 mm).

Both ovaries are normal in size and echotexture.

No free fluid or collection seen. No basal pleural effusion seen.

No significant lymphadenopathy seen.

No dilated bowel loop seen.

IMPRESSION:- Grade I fatty infiltration of liver.

Please correlate clinically.....

.....End of Report.....

Prepare By. MD.SERAJ DR. ALOK KUMAR, M.B.B.S,M.D,DMRD CONSULTANT

Note : The information in this report is based on interpretation of images. This report is not the diagnosis and should be correlated with clinical details and other investigation.